NYSE:SYK Stryker (SYK) Stock Price, News & Analysis $358.92 +0.92 (+0.26%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$355.72▼$361.0650-Day Range$315.94▼$360.4252-Week Range$249.98▼$364.36Volume1.00 million shsAverage Volume1.30 million shsMarket Capitalization$136.78 billionP/E Ratio40.97Dividend Yield0.89%Price Target$377.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Stryker alerts: Email Address Stryker MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside5.1% Upside$377.11 Price TargetShort InterestHealthy1.05% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-0.95Upright™ Environmental ScoreNews Sentiment0.92Based on 10 Articles This WeekInsider TradingSelling Shares$68.33 M Sold Last QuarterProj. Earnings Growth12.08%From $12.00 to $13.45 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector56th out of 910 stocksSurgical & Medical Instruments Industry7th out of 95 stocks 2.4 Analyst's Opinion Consensus RatingStryker has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageStryker has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stryker's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.05% of the float of Stryker has been sold short.Short Interest Ratio / Days to CoverStryker has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stryker has recently increased by 17.92%, indicating that investor sentiment is decreasing significantly. Previous Next 3.3 Dividend Strength Dividend YieldStryker has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthStryker has been increasing its dividend for 31 years.Dividend CoverageThe dividend payout ratio of Stryker is 36.53%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Stryker will have a dividend payout ratio of 23.79% next year. This indicates that Stryker will be able to sustain or increase its dividend.Read more about Stryker's dividend. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStryker has received a 60.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Protective clothing", "Synthetic bone grafts", "Surgery simulation software", "Medical laboratory equipment", and "Bone cement" products. See details.Environmental SustainabilityThe Environmental Impact score for Stryker is -0.95. Previous Next 2.2 News and Social Media Coverage News SentimentStryker has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Stryker this week, compared to 12 articles on an average week.Search InterestOnly 13 people have searched for SYK on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is a decrease of -15% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stryker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,330,400.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Stryker is held by insiders.Percentage Held by Institutions77.09% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stryker's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Stryker are expected to grow by 12.08% in the coming year, from $12.00 to $13.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stryker is 40.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Stryker is 40.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Earnings Growth RatioStryker has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioStryker has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stryker's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Stryker Stock (NYSE:SYK)Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.Read More SYK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYK Stock News HeadlinesAugust 29, 2024 | insidertrades.comStryker Co. (NYSE:SYK) Insider Sells $213,000.00 in StockAugust 23, 2024 | marketbeat.comDiabetes and Neuro Products Ignite Medtronic’s Q1 Earnings RallyMedtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance.September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 10, 2024 | insidertrades.comStryker Co. (NYSE:SYK) Director Ronda E. Stryker Sells 190,000 SharesAugust 7, 2024 | marketbeat.comMedical Technology Stock Benefits from Rising Acute Care DemandMedical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry.September 6 at 4:50 PM | seekingalpha.comStryker Corporation (SYK) Wells Fargo 2024 Healthcare Conference (Transcript)September 2, 2024 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Stryker (SYK)August 30, 2024 | americanbankingnews.comStryker (NYSE:SYK) PT Raised to $374.00 at BTIG ResearchSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 29, 2024 | americanbankingnews.comBrokerages Set Stryker Co. (NYSE:SYK) PT at $373.11August 28, 2024 | msn.comStryker Corporation (SYK): Among The Best Medical AI CompaniesAugust 28, 2024 | finance.yahoo.comInstitutional investors control 79% of Stryker Corporation (NYSE:SYK) and were rewarded last week after stock increased 4.5%August 28, 2024 | benzinga.comDeep Dive Into Stryker Stock: Analyst Perspectives (11 Ratings)August 27, 2024 | uk.finance.yahoo.comTop Stock Reports for Toyota Motor, IBM & StrykerAugust 27, 2024 | morningstar.comStryker Currently Up 11 Days Straight, On Pace for Longest Winning Streak Since October 2014 — Data TalkAugust 26, 2024 | markets.businessinsider.comStryker’s Strategic Acquisition of Vertos Medical Bolsters Buy Rating and $360 Price TargetAugust 24, 2024 | marketwatch.comStryker Corp. stock rises Friday, still underperforms marketAugust 23, 2024 | msn.comStryker Road Run reaches funding milestone for CUH Charity Children’s UnitSee More Headlines Receive SYK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/31 Dividend6/28/2024Last Earnings7/30/2024Dividend Payable7/31/2024Today9/07/2024Ex-Dividend for 10/31 Dividend9/30/2024Dividend Payable10/31/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:SYK CUSIP86366710 CIK310764 Webwww.strykercorp.com Phone(269) 385-2600Fax269-385-1062Employees52,000Year Founded1941Price Target and Rating Average Stock Price Target$377.11 High Stock Price Target$406.00 Low Stock Price Target$345.00 Potential Upside/Downside+5.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$8.76 Trailing P/E Ratio40.97 Forward P/E Ratio29.91 P/E Growth2.78Net Income$3.17 billion Net Margins16.12% Pretax Margin18.78% Return on Equity22.89% Return on Assets11.03% Debt Debt-to-Equity Ratio0.51 Current Ratio1.68 Quick Ratio0.95 Sales & Book Value Annual Sales$20.50 billion Price / Sales6.67 Cash Flow$13.36 per share Price / Cash Flow26.87 Book Value$51.86 per share Price / Book6.92Miscellaneous Outstanding Shares381,080,000Free Float358,474,000Market Cap$136.78 billion OptionableOptionable Beta0.91 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Kevin A. Lobo (Age 59)Chairman, CEO & President Comp: $5.7MMr. Glenn S. Boehnlein (Age 62)VP & CFO Comp: $2.27MMr. Viju S. Menon (Age 56)Group President of Global Quality & Operations Comp: $1.68MMr. J. Andrew Pierce (Age 50)Group President of MedSurg & Neurotechnology Comp: $2.03MMr. Spencer S. Stiles (Age 47)Group President of Orthopaedics & Spine Comp: $2.02MMr. William E. Berry Jr. (Age 58)VP & Chief Accounting Officer Mr. Robert C. CohenCTO and VP of Global R&D - Joint ReplacementMr. Alan DouvilleVP, Chief Information Officer & Chief Information Security OfficerMr. Jason BeachVice President of Finance & Investor RelationsMr. Robert S. Fletcher (Age 53)VP & Chief Legal Officer Comp: $895.89kMore ExecutivesKey CompetitorsAbbott LaboratoriesNYSE:ABTIntuitive SurgicalNASDAQ:ISRGBoston ScientificNYSE:BSXMedtronicNYSE:MDTBecton, Dickinson and CompanyNYSE:BDXView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 57,509 shares on 9/5/2024Ownership: 0.015%Clear Rock Advisors LLCBought 140 shares on 9/3/2024Ownership: 0.003%Pensioenfonds Rail & OVSold 1,907 shares on 8/30/2024Ownership: 0.027%Centennial Bank AR Bought 48 shares on 8/30/2024Ownership: 0.000%Maven Securities LTDBought 9,300 shares on 8/29/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Stryker Stock? SYK Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Stryker Co.: Stryker Co. has consistently shown strong financial performance with a solid return on equity of 22.89%, indicating efficient use of shareholder funds. The company has a diverse product portfolio across its MedSurg, Neurotechnology, and Orthopaedics and Spine segments, reducing dependency on any single market. Recent insider selling activities, including the CFO selling shares at $333.00, could indicate confidence in the company's future performance. Stryker Co. announced a quarterly dividend of $0.80 per share, reflecting a stable dividend payout ratio of 36.53% and a yield of 0.89% for investors seeking income. Analysts have given Stryker Co. an average rating of "Moderate Buy" with a target price of $373.84, suggesting potential upside for investors based on market expectations. Cons Investors should be bearish about investing in Stryker Co. for these reasons: The recent insider selling activities, with insiders selling a significant number of shares, may raise concerns about the company's future growth prospects. Stryker Co.'s stock price has been relatively stagnant, trading down 0.2% recently, which could indicate limited short-term price appreciation potential. The company's P/E ratio of 41.14 and price-to-earnings-growth ratio of 2.78 suggest that the stock may be currently overvalued compared to its growth prospects. While the company has a strong market capitalization of $137.35 billion, the beta of 0.89 indicates that the stock may be less volatile than the market average, potentially limiting potential returns for risk-seeking investors. Despite positive earnings results, Stryker Co. faces competition in the medical technology sector, which could impact its market share and profitability in the long term. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com. SYK Stock Analysis - Frequently Asked Questions How have SYK shares performed this year? Stryker's stock was trading at $299.46 at the beginning of 2024. Since then, SYK stock has increased by 19.9% and is now trading at $358.92. View the best growth stocks for 2024 here. How were Stryker's earnings last quarter? Stryker Co. (NYSE:SYK) released its quarterly earnings data on Tuesday, July, 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. The firm's revenue for the quarter was up 8.5% compared to the same quarter last year. Read the conference call transcript. What is Kevin A. Lobo's approval rating as Stryker's CEO? 1,492 employees have rated Stryker Chief Executive Officer Kevin A. Lobo on Glassdoor.com. Kevin A. Lobo has an approval rating of 97% among the company's employees. This puts Kevin A. Lobo in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Stryker have any subsidiaries? The following companies are subsidiaries of Stryker: Vocera Communications, Vocera, Gauss Surgical, OrthoSensor, Wright Medical Group, Cardan Robotics, Mobius Imaging, and others. Who are Stryker's major shareholders? Stryker's top institutional investors include Bank of New York Mellon Corp (1.49%), First Western Trust Bank (0.92%), Legal & General Group Plc (0.75%) and Clearbridge Investments LLC (0.61%). Insiders that own company stock include Ronda E Stryker, Kevin Lobo, James Andrew Pierce, Allan C Golston, M Kathryn Fink, Viju Menon, Robert S Fletcher, Srikant M Datar, William E Berry Jr and Glenn S Boehnlein. View institutional ownership trends. How do I buy shares of Stryker? Shares of SYK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stryker own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stryker investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Home Depot (HD), Medtronic (MDT), Visa (V), AbbVie (ABBV) and Cisco Systems (CSCO). This page (NYSE:SYK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stryker Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYK Stock Alerts